Welcome to our dedicated page for Kalvista Pharm SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KalVista Pharmaceuticals SEC filings document 8-K disclosures for a commercial-stage pharmaceutical company focused on oral rare-disease therapies. The filings cover results of operations and financial condition, Regulation FD materials, product-revenue updates tied to EKTERLY, and the company’s Nasdaq-listed common stock.
The filing record also includes governance and compensation disclosures, board committee changes, executive appointments, material definitive agreements, and capital-structure actions. Financing disclosures include the completed sale of 3.250% convertible senior notes due 2031, while other reports describe exhibit filings, furnished press releases, Inline XBRL cover data, and formal disclosure treatment under the Exchange Act.
KalVista Pharmaceuticals' Chief Operations Officer, Arif Bilal, reported the cash-out of equity awards tied to the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, 49,000 restricted stock units and 100,000 stock options were disposed of to the issuer as part of a completed merger.
Under the Merger Agreement, Chiesi’s subsidiary acquired all outstanding KalVista common shares for $27.00 per share in cash, then merged with KalVista, which now operates as a wholly owned subsidiary. Unexercised options with an exercise price below the $27.00 merger consideration and outstanding RSUs were fully vested, cancelled, and converted into cash payments based on formulas set in the agreement, while underwater options were cancelled with no payment.
KalVista Pharmaceuticals director Reid Laurence reported the disposition of a stock option grant in connection with the company’s acquisition by Chiesi Farmaceutici. A stock option covering 17,000 shares of common stock with a per share exercise price of $10.07 was surrendered to the issuer.
Under the merger agreement, a Chiesi subsidiary completed a cash tender offer for all outstanding KalVista common shares at $27.00 per share, after which the subsidiary merged into KalVista on June 11, 2026, making KalVista a wholly owned subsidiary. Per the merger terms, in-the-money options such as this one became fully vested, were cancelled, and converted into the right to receive a cash payment based on the difference between the merger price and the option exercise price, multiplied by the number of option shares. Options with exercise prices at or above $27.00 were cancelled for no consideration.
KalVista Pharmaceuticals director Edward W. Unkart disposed of stock options in connection with the company’s acquisition by Chiesi Farmaceutici. On June 11, 2026, he surrendered a total of 109,000 stock options to the issuer in multiple transactions coded as dispositions to issuer.
According to the merger agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, after which the merger closed and KalVista became a wholly owned subsidiary. Each outstanding in-the-money option was cancelled and converted into a right to receive cash equal to the spread between the $27.00 consideration and its exercise price, multiplied by the number of underlying shares.
KalVista Pharmaceuticals chief executive officer Benjamin L. Palleiko reported the disposition of his equity in connection with the company’s merger with Chiesi Farmaceutici. A total of 479,989 shares of common stock and multiple restricted stock units and stock options were cancelled and converted into cash rights under the merger terms at a cash price of $27.00 per share for common stock or, for in-the-money options, the cash value of the spread. Following these transactions, the filing shows no remaining reported holdings for these securities.
KalVista Pharmaceuticals chief development officer Christopher Yea reported dispositions of all his equity in connection with the company’s merger with Chiesi Farmaceutici. A tender offer and subsequent merger converted issued and outstanding common shares into cash at $27.00 per share, subject to tax withholding. Yea disposed of 229,918 shares of common stock and multiple restricted stock unit and stock option awards, which were cancelled under the merger terms. Vested options with exercise prices below $27.00 were converted into cash payments based on the spread, while options at or above that price were cancelled without consideration, leaving him with no remaining reported holdings.
KalVista Pharmaceuticals’ Chief Financial Officer Brian Piekos disposed of his equity awards in connection with the company’s cash sale to Chiesi Farmaceutici. He returned 21,661 shares of common stock to the issuer and cancelled 93,750 and 55,000 share restricted stock unit awards.
Pursuant to the merger agreement, Chiesi’s subsidiary completed a cash tender offer for all KalVista common shares at $27.00 per share, after which the acquirer merged with KalVista. Outstanding stock options with exercise prices below the $27.00 merger consideration, including 100,000 options at $11.87 per share, and all RSUs became fully vested and were converted into rights to receive cash, leaving Piekos with no remaining reported holdings.
KalVista Pharmaceuticals, Inc. filed Post-Effective Amendment No. 1 to its Form S-3 to deregister any securities remaining unsold under Registration No. 333-280759. The amendment states KalVista completed a merger on June 11, 2026 with Skyline Merger Sub, Inc., making KalVista a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.
The amendment removes from registration all securities that remained unsold or unissued under the Registration Statement and terminates the Registration Statement’s effectiveness. The filing references the Merger Agreement dated April 29, 2026 and attaches that agreement as an exhibit to a prior Form 8-K.
KalVista Pharmaceuticals, Inc. notified removal of its Common Stock from listing and registration on the Nasdaq Stock Market LLC under Form 25. The notification states the Exchange and the Issuer have complied with the procedures of 17 CFR 240.12d2-2 for voluntary withdrawal.
The filing lists Nasdaq Stock Market LLC as the submitting exchange and includes the issuer's corporate address in Wiltshire, United Kingdom. The action is described as a withdrawal/strike from listing under the cited Exchange Act rule.
KalVista Pharmaceuticals completed a cash tender offer and merger at $27.00 per share. The offer expired at one minute after 11:59 p.m. Eastern on June 10, 2026, and 43,152,532 Shares were validly tendered and accepted, representing approximately 77.8% of outstanding Shares as of the Expiration Date.
Following acceptance of tendered Shares, Purchaser merged with and into the Company under Section 251(h) of the DGCL. Each remaining outstanding Share (other than excluded Shares) was converted into the right to receive $27.00 per Share, net to the seller in cash, without interest and subject to applicable tax withholding. A joint press release dated June 11, 2026 announcing the closing is attached as an exhibit.
KalVista Pharmaceuticals amended its Solicitation/Recommendation Statement to report completion of the tender offer and merger. The Offer expired one minute after 11:59 p.m. Eastern Time on June 10, 2026, with 43,152,532 Shares validly tendered and not withdrawn, representing approximately 77.8% of outstanding shares as of the Expiration Date. The tender satisfied the Minimum Condition; Purchaser accepted and will pay for all validly tendered shares at $27.00 per Share. Following satisfaction (or waiver) of remaining conditions, Purchaser merged with and into the Company under Section 251(h) of the DGCL. Each outstanding share not purchased in the Offer was converted into the right to receive $27.00 per Share. As a result of the Merger, the common stock will be delisted from and deregistered under the Nasdaq Global Market.